Literature DB >> 19001318

Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome.

Shannon N Westin1, Robin A Lacour, Diana L Urbauer, Rajyalakshmi Luthra, Diane C Bodurka, Karen H Lu, Russell R Broaddus.   

Abstract

PURPOSE: Endometrial carcinoma in the lower uterine segment (LUS) is a poorly described cancer that can be clinically confused with endocervical carcinoma. We performed a case-comparison study to document the clinicopathologic characteristics of LUS tumors and their association with risk factors for endometrial cancer. PATIENTS AND METHODS: The clinical records and pathology reports from women who underwent hysterectomy at our institution for endometrial or endocervical adenocarcinoma over an 11-year interval were reviewed. The LUS group consisted of women with endometrial tumors that clearly originated between the lower uterine corpus and the upper endocervix. Immunohistochemistry and microsatellite instability and MLH1 methylation assays were performed.
RESULTS: Thirty-five (3.5%) of 1,009 women had endometrial carcinoma of the LUS. Compared with patients with corpus tumors, LUS patients were younger, had higher stage tumors, and had more invasive tumors. Preoperative diagnosis of the LUS tumors more frequently included the possibility of endocervical adenocarcinoma. Seventy-three percent of the LUS tumors had an immunohistochemical expression pattern typical of conventional endometrioid adenocarcinoma. Ten (29%) of 35 women with LUS tumors were confirmed to have Lynch syndrome or were strongly suspected to have Lynch syndrome on the basis of tissue-based molecular assays.
CONCLUSION: The prevalence of Lynch syndrome in patients with LUS endometrial carcinoma (29%) is much greater than that of the general endometrial cancer patient population (1.8%) or in endometrial cancer patients younger than age 50 years (8% to 9%). On the basis of our results, the possibility of Lynch syndrome should be considered in women with LUS tumors.

Entities:  

Mesh:

Year:  2008        PMID: 19001318      PMCID: PMC2645115          DOI: 10.1200/JCO.2008.18.6296

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  25 in total

1.  Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma.

Authors:  Russell R Broaddus; Henry T Lynch; Lee-May Chen; Molly S Daniels; Peggy Conrad; Mark F Munsell; Kristin G White; Rajyalakshmi Luthra; Karen H Lu
Journal:  Cancer       Date:  2006-01-01       Impact factor: 6.860

2.  Histochemical investigation of epithelial mucosubstances in the uterine isthmus.

Authors:  T E Sorvari; L Laakso
Journal:  Obstet Gynecol       Date:  1970-07       Impact factor: 7.661

3.  Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome?

Authors:  Miina Ollikainen; Wael M Abdel-Rahman; Anu-Liisa Moisio; Annette Lindroos; Reetta Kariola; Irma Järvelä; Minna Pöyhönen; Ralf Butzow; Päivi Peltomäki
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

4.  Cytopathological observations in a 27-year-old female patient with endometrioid adenocarcinoma arising in the lower uterine segment of the uterus.

Authors:  K Masuda; C Yutani; K Akutagawa; S Yamamoto; H Ishibashi-Ueda; M Imakita; M Takeda; A Kurata; T Hayashi; M Sasaki
Journal:  Diagn Cytopathol       Date:  1999-08       Impact factor: 1.582

5.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

6.  Tumors of the uterine isthmus: clinicopathologic features and immunohistochemical characterization of p53 expression and hormone receptors.

Authors:  S M Jacques; F Qureshi; N C Ramirez; V K Malviya; W D Lawrence
Journal:  Int J Gynecol Pathol       Date:  1997-01       Impact factor: 2.762

7.  Adenocarcinoma involving the uterine cervix: magnetic resonance imaging findings in tumours of endometrial, compared with cervical, origin.

Authors:  Masoom A Haider; Michael Patlas; Kartik Jhaveri; William Chapman; Anthony Fyles; Barry Rosen
Journal:  Can Assoc Radiol J       Date:  2006-02       Impact factor: 2.248

8.  Carcinoma of the lower uterine segment. Clinicopathologic analysis of 12 cases.

Authors:  T Hachisuga; T Kaku; M Enjoji
Journal:  Int J Gynecol Pathol       Date:  1989       Impact factor: 2.762

9.  Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study.

Authors:  R C Boronow; C P Morrow; W T Creasman; P J Disaia; S G Silverberg; A Miller; J A Blessing
Journal:  Obstet Gynecol       Date:  1984-06       Impact factor: 7.661

10.  The immunohistochemical discrimination of endometrioid adenocarcinomas.

Authors:  D J Dabbs; K Sturtz; R J Zaino
Journal:  Hum Pathol       Date:  1996-02       Impact factor: 3.466

View more
  55 in total

1.  Lower uterine segment involvement is associated with poor outcomes in early-stage endometrioid endometrial carcinoma.

Authors:  Nora T Kizer; Feng Gao; Saketh Guntupalli; Premal H Thaker; Matthew A Powell; Paul J Goodfellow; David G Mutch; Israel Zighelboim
Journal:  Ann Surg Oncol       Date:  2010-12-22       Impact factor: 5.344

2.  Risk factors for developing multiple malignancies in patients with endometrial cancer.

Authors:  Stefano Uccella; Stephen S Cha; L Joseph Melton; Eric J Bergstralh; Lisa A Boardman; Gary L Keeney; Karl C Podratz; Fabio Francesco Ciancio; Andrea Mariani
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

Review 3.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 4.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

5.  Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.

Authors:  Qiong Gan; Suzanne Crumley; Russell R Broaddus
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

6.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25

7.  Uterine endometrial carcinoma with DNA mismatch repair deficiency: magnetic resonance imaging findings and clinical features.

Authors:  Kiyoyuki Minamiguchi; Junko Takahama; Tomoko Uchiyama; Ryosuke Taiji; Natsuhiko Saito; Hiroshi Okada; Nagaaki Marugami; Yasuhito Tanase; Ryuji Kawaguchi; Chiho Ohbayashi; Hiroshi Kobayashi; Toshiko Hirai; Kimihiko Kichikawa
Journal:  Jpn J Radiol       Date:  2018-05-04       Impact factor: 2.374

8.  Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Kari L Ring; Molly Daniels; Bryan M Fellman; Diana L Urbauer; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-13

9.  Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.

Authors:  Brittany A L Batte; Amanda S Bruegl; Molly S Daniels; Kari L Ring; Katherine M Dempsey; Bojana Djordjevic; Rajyalakshmi Luthra; Bryan M Fellman; Karen H Lu; Russell R Broaddus
Journal:  Gynecol Oncol       Date:  2014-06-14       Impact factor: 5.482

10.  Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.

Authors:  Kari L Ring; Amanda S Bruegl; Brian A Allen; Eric P Elkin; Nanda Singh; Anne-Renee Hartman; Molly S Daniels; Russell R Broaddus
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.